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Parathyroid carcinoma is a malignant neoplasm affecting 05e2 per cent of all patients with primary
hyperparathyroidism that was ﬁrst described by de Quevain in 1904. To day it continues to defy diagnosis
and treatment. It is difﬁcult to diagnose in part because of its rarity, lack of deﬁnitive diagnostic markers
and overlapping clinical features of benign primary hyperparathyroidism. As a result initial surgical
treatment is inadequate essentially leading to disease recurrence where complete cure is unlikely. En
bloc surgical resection remains the only curative treatment, and high priorities are improving diagnostic
methods, and clinical staging for resection once the disease is suspected. Margin status at resection is
related to prognosis. Thus, a trend towards aggressive surgical management has improved outcomes. The
recurrence rate of parathyroid carcinoma is as high as 80% with survival rates <50% at 10 years. Results of
chemotherapy are disappointing. However, recent trials using radiation therapy are promising, but
require further study.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Parathyroid carcinoma is an uncommon malignancy mostly
seen in patients treated for primary Hyperparathyroidism (PHPT)
and is the least common endocrine malignancy accounting for only
0.005% of reported cases.1 This disease was ﬁrst described in 1904
by de Quevain2 in a patient who presented with a non-functioning
lesion. Subsequently, in 1933, Sainton and Millot3 described the
ﬁrst functioning parathyroid carcinoma. It is a slow-growing tumor
of low malignant potential but frustrating and difﬁcult clinical
problem. The majority of patients are diagnosed between ages 45
and 60 years, but the tumor arises over a wide age range.4 In most
series, parathyroid carcinoma accounts for less than 1% of patients
with PHPT.5e7 However, it can also occur as a non-functioning
lesion in patients with normal parathyroid function,8 Table 1. The
exact cause of parathyroid carcinoma is unknown, and most cases
occur sporadically, but there are several clinical situations that may
predispose to the development of this cancer. The most common of
these are a history of neck irradiation,9,10 Parathyroid adenoma or
a hyperplastic parathyroid gland,11,12 and prolonged secondary
hyperparathyroidism.13,14 Parathyroid carcinoma may also occur inulty of Medicine, Clinic for
gery, OKL, Liebig Strasse 20,
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ciates Ltd. Published by Elsevier Ltassociation with familial HPT or multiple endocrine neoplasia
(MEN) type I syndrome.15
The reported incidence of parathyroid carcinoma is may be
somewhat more common in Japan and Italy than in the rest of the
west, accounting for 5%e5.2% of patients with PHPT.16e18 Previous
studies indicate that this wide variation may be due to genetic or
environmental inﬂuences, local referral practice or may even
represent underdiagnosis or overdiagnosis.19 No other dispropor-
tionate clustering such as by gender, age and ethnicity/race was
observed.1 Patients with this entity typically present at advanced
stage with symptomatic hypercalcemia, osteolytic bone changes,
and renal impairment, and cure rates are low, evenwith aggressive
therapy.5,20,21 Morbidity and Mortality are always related to
metabolic complications due to severe hypercalcemia. Making
a deﬁnitive diagnosis of parathyroied carcinoma when the macro-
scopic and microscopic ﬁndings are ambiguous is difﬁcult. It is
difﬁcult to diagnose in part because of its rarity, the limited
knowledge regarding its natural history, and its clinical course,
which is that of benign primary hyperparathyroidism. As a result
initial surgical treatment is inadequate essentially leading to
disease recurrence where complete cure is unlikely.22 Whether
functional or non-functional, this tumor can often be difﬁcult to
differentiate from benign parathyroid adenoma and diagnosis has
been always based on both clinical and histological criteria.4 In this
reviewwe discuss etiologic factors, molecular pathogenesis, clinical
features, diagnosis and contemporary management of parathyroid
carcinoma.d. All rights reserved.
Table 1
Published collective series of parathyroid carcinoma.
Author Year N
Wilkins et al.4 1920e2009 19*
Holmes et al.71 1933e1968 41
Shane et al.5 1969e1981 62
Obara et al.30 1981e1989 163
Koea et al.29 1990e1999 94
Hundahl et al.1 1985e1995 286**
* Non-functioning parathyroid carcinomas.
** Parathyroid carcinomas in the USA.
Table 2
Factors that may predispose to the development of parathyroid carcinoma.
History of irradiation of the head and neck9,10,13
Familial isolated primary hyperparathyroidism (PHPT)15,24
Hereditary hyperparathyroid-jaw tumor syndrome (HPT-JT)4,24
Multiple endocrine neoplasia syndromes (MEN-1 and MEN-2A)25e27
Parathyroid adenoma or hyperplastic parathyroid gland11,12,31
Prolonged secondary hyperparathyroidism14
End-stage renal disease32
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Several etiologic factors are associated with parathyroid carci-
noma (Table 2), although most cases occur in the absence of any of
them. A strong association exists between parathyroid carcinoma
and hyperparathyroidism-jaw tumor (HPT-JT) syndrome. HPT-JT is
an autosomal dominant disease characterized by the occurrence of
parathyroid and ﬁbro-osseous tumors of the jaw bones.23 The
prevalence of parathyroid carcinoma has been estimated as high as
15% in patients with HPT-JT.4,24
Other clinical conditions that are etiological factors for para-
thyroid carcinoma include familial hyperparathyroidism, a rare
autosomal dominant disorder,25e27 and multiple endocrine
neoplasia (MEN) type-1. MEN type-1 is a separate entity from that
of familial hyperparathyroidism and also carries an increased risk
for parathyroid carcinoma.28 Previous radiation to the neck is
known to be a risk factor for head and neck cancer and thismay also
holds for parathyroid carcinoma and this association has been
reported in several cases of parathyroid cancer.9,10,13,29,30 Further-
more, parathyroid cancer has been reported in association with
Hyperplastic parathyroid gland,11,12,31 secondary hyperparathy-
roidism,14 and end-stage renal disease.321.2. Tumor biology
The majority of all human malignancies including parathyroid
carcinoma is sporadic and arises from the acquisition of somatic,
genetic and epigenetic alterations leading to changes in gene
sequences, structure, copy number and expression. A number of
different molecular defects have been reported in parathyroid
carcinoma. These mutations primarily involve oncogenes and
tumor suppressor genes, suggesting that these cancers likely
develop due to a series of cellular injuries. Signiﬁcant evidence
exists for the presence of genes whose acquired activation or
inactivation contributes to the development of parathyroid carci-
noma. In one study, losses of 1p, 4q and 13q, and gains of 1q, 9q,16pTable 3
Functioning and Non-functioning parathyroid carcinoma and benign PHPT: comparison
PCA (functioning)
Average Age 45
FMR 1
Serum calcium markedly elevated (>14 g/dl)
PTH markedly elevated (3e10x an)
Symptoms of hypercalcemia yes (>98%)
Palpable neck mass common (30e76%)
Renal involvement common (32e80%)
Skeletal involvement common (34e91%)
Local recurrence after SPTX common (>50%)
Overall survival rate after SPTX <53%
Local recurrence after EBR rare (<8%)
Overall survival rate EBR >89%
Distant Metastases yes (LN, lung, bone, liver)
PCA, parathyroid carcinoma; PHPT, primary hyperparathyroidism; PTH, parathyroid horm
bloc resection (resection of the involved gland and a surrounding margin of normal tissand Xq, were more commonly observed in parathyroid carcinoma
than in benign adenomas.33 Others have demonstrated mutations
in genes that are involved in the regulation of cell cycle activity
such as parathyroid adenoma 1 gene (PRAD1), p53 and retino-
blastoma (RB) tumor suppressor genes that may contribute
towards malignant transformation.24,34
PRAD1 or cyclin D1 is an oncogene located at chromosome band
11q13. Its protein product is a cell cycle regulator.35 Many reports
have implicated Overexpression of cyclin D1 in parathyroid carci-
noma.34,36 Cyclin D1 has been identiﬁed in up to 91% of such
tumors.34 Furthermore, the presence of a gene on chromosome 13
whose acquired inactivation contributes to the development of
parathyroid cancer has also been demonstrated.37,38 This deletion
contains the coding regions for the retinoblastoma (RB) and
hereditary breast carcinoma susceptibility gene (BRCA2) tumor
suppressor genes. Together with cyclin D1, Retinoblastoma, the
classic tumor suppressor gene, is important in cell cycle control.
A more recently described tumor suppressor gen is the HRPT2
gene. This gene encodes the paraﬁbromin protein, and is associated
with the HPT-JT syndrome.39 Inactivating germ-line Mutations in
this gene were recently identiﬁed in sporadic parathyroid
carcinomas.40
P53 tumor suppressor gene is another cell cycle regulator and
awell-established frequent participant in human carcinomas.41 The
role of p53 tumor suppressor gene in parathyroid carcinoma has
been examined and no coding region mutations were identi-
ﬁed.37,42 This implies no major contributions of this gene to the
pathogenesis of Parathyroid carcinoma.
Taken together, although there is much speculation regarding
the factors that induce the various mutations, little or nothing is
known about how these factors actually cause parathyroid cancer.
2. Diagnosis
2.1. Clinical presentation
The typical age of presentation of parathyroid carcinoma is the
ﬁfth decade of life, about as much as two decades earlier comparedof clinical features4,8,17,24,29,35.
PCA (non-functioning) PHPT
49 55
1.3 3.5
normal above upper limit of normal
normal mildly elevated
no rare (<20%)
common (>80%) rare
not known rare
not known rare
common (>50%) na
<53% na
rare (<8%) na
>89% na
yes (LN, lung,
bone, liver)
na
one; SPTX, simple parathyroidectomy (excision of the involved gland alone); EBR, En
ue); an, above normal; na, not applicable; LN, Lymph node.
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cases present between the ages 45 and 60 years.4
However, these tumors may arise over a wide age range.
Apparently parathyroid carcinoma has a considerably lower female
to male ratio than that generally observed in benign HPT (Table 3).
Hyperparathyroidism occurs in more than 90% of Patients. As
a result the most common presenting symptoms of parathyroid
carcinoma are caused by severe hypercalcemia and include renal
colic, painful joints, bone or low back pain, thirst, nocturia, poly-
dipsia, anorexia, abdominal Pain, constipation and fatigue.4,22,43
Clinically, a patient with primary hyperparathyroidism is most
likely to have a parathyroid adenoma. The Overlap in symptoms
between functioning parathyroid carcinoma and benign HPTmakes
it difﬁcult to differentiate between both entities. As a result, para-
thyroid carcinoma is most often misdiagnosed and mismanaged as
benign primary hyperparathyroidism.44 Given the rarity of this
malignancy, and the surgeon’s expectation of parathyroid adenoma
for which simple gland removal is appropriate, this situation is not
surprising. Clues that the patient may have parathyroid carcinoma
include, severe hypercalcemia (>14 mg/dl) or extremely high
serum PTH levels (>5 the upper limit of normal),45 and a palpable
neck mass with hoarseness due to unilateral vocal cord paralysis
indicating involvement of the recurrent laryngeal nerve in a patient
without a previous neck surgery.30,43 The diagnosis of non-func-
tioning parathyroid carcinoma is even more difﬁcult than for
functioning parathyroid carcinoma, primarily due to lack of
symptoms until late in the disease course. This extremely rare
subtype of parathyroid carcinoma has been reported to present
with locally advanced neck masses.8,46
2.2. Laboratory tests
Biochemical tests, such as the intact PTH and serum calcium
levels, thoughmost common indicator of Hyperparathyroidism, are
of little Help in accurately differentiating parathyroid carcinoma
from benign PHPT, since they all can be associated with both
conditions.20 However, Hypercalcemia in parathyroid carcinoma is
usually profound, with serum calcium concentrations 3e4 mg/dl
above the upper limit of normal and PTH levels as high as 75
fold.35,47 This is in contrast to the values of PTH and Calcium found
in benign PHPT, which are mildly elevated or near the upper limit of
normal in themajority of cases. These patientsmay ormay not have
symptoms and are often discovered while being investigated for an
unrelated condition.24 In addition, some patients with parathyroid
carcinoma have elevated alkaline phosphatase, Hypophsphatemia,
and hyperchloremic metabolic acidosis.16,48 No potential speciﬁc
tumormarker of parathyroid carcinoma thatmay show some utility
as an aid in the diagnosis of carcinoma has been jet identiﬁed.
2.3. Imaging
Although the presence of functioning parathyroid carcinoma or
residual disease can be suspected by measuring the intact serum
PTH level, the localization of all tumor sites remains a clinical
challenge. The initial diagnostic imaging procedure to evaluate
a patient with suspected parathyroid carcinoma or residual disease
is neck ultrasound. This imaging modality is fast and inexpensive,
and may help to differentiate benign parathyroid adenoma from
parathyroid carcinoma. The normal parathyroid gland is typically
not visualized because of its deep location and small size. Para-
thyroid adenoma and parathyroid carcinoma may be detected as
mass lesions. While large size, inhomogeneous appearance, and
irregular borders may point toward parathyroid carcinoma, ovoid,
well-marginated solid lesions indicate parathyroid adenoma.49
Study results indicate a sensitivity ranging from 27% to 97% fordetecting adenomas and 50%e90% for carcinomas.50,51 In a recent
meta-analysis this ﬁgure increases to 79% and 100% respectively.52
The wide range of sensitivities is reﬂective of the difﬁculties
inherent to this examination indicating the limited utility of
ultrasound to distinguish parathyroid carcinoma from parathyroid
adenoma. Generally, the sensitivity and speciﬁcity of ultrasound
varywith the location of parathyroid carcinoma,53 the quality of the
equipment, the presence of concomitant thyroid disease,54 and the
experience of the operator. In a report from Ruda et al.52 about 62%
of undetected lesions were greater than 2 cm in diameter, where as
75% of detected lesions were less than 2 cm in diameter. The results
of this study imply that size is not necessarily a limiting factor.
99mTc sestamibi scanning is like ultrasound among the primary
means of assessing parathyroid lesions. This method relies on
different radiotracer uptake patterns and kinetics between the
thyroid gland, the normal parathyroid gland, and the abnormal
parathyroid gland. It is effective in localizing abnormal parathyroid
lesion, and has a sensitivity and speciﬁcity as high as 85% and 96%
respectively.55,56 Because it allow for whole-body scanning, it has
been used successfully for preoperative localization of parathyroid
carcinoma and particularly to detect metastatic disease.57 However,
this nuclear medicine imaging method is not 100% parathyroid
speciﬁc, so that detection of abnormal parathyroid glands requires
in addition to altered tracer kinetics in the abnormal gland, unal-
tered kinetics in the surrounding structures. Unfortunately, such
a ﬁnding das not always exist. For example, thyroid nodules
including adenomas and carcinomas can have very prominent
99mTc sestamibi with marked tracer retention on delayed imaging,
mimicking a parathyroid adenoma.58 Single photon emission
computed tomography (SPECT), SPECT-CT, when available, can be
quite useful in simplifying the localization of a parathyroid lesion,
improving the sensitivity of 99mTc sestamibi scintigraphy.59
Contrasted computed tomography (CT) is may be useful in
identifying ectopic lesions in the neck and recurrent parathyroid
carcinoma, although this test also lacks sensitivity in diagnosing
parathyroid carcinoma. In one series of 8 patients, the sensitivity of
contrast-enhanced CT in identifying recurrent parathyroid carci-
nomawas only 53%.60 When interpreting CT of parathyroid disease,
it is almost mandatory to have additional imaging in the form of
ultrasonography or 99mTc sestamibi scanning in order to ﬁnd out
the most likely location of the abnormal glands and differentiate
the parathyroid gland from non pathologic lymph nodes and other
unrelated ﬁndings.61 Therefore, CT is used as an additional diag-
nostic tool in the management of de novo or, more commonly,
recurrent parathyroid carcinoma. However, visualization of
pulmonary, tracheoesophageal groove and superior mediastinal
metastases is best achieved by contrasted CT.62
Ultrasound, sestamibi scanning and CT are useful diagnostic
tools for detecting cervical parathyroid recurrences. However,
magnetic resonance imaging (MRI) with fat suppression is superior
and permits excellent visualization of recurrent lesions.63 It can
raise the diagnostic sensitivity to as high as 93%; is non invasive,
does not involve exposure to radiation and avoids the artifacts
produced by surgical clips that make interpretation of CT difﬁcult.22
Therefore, MRI is optimally suited in helping to navigate the
complex anatomy of the neck, delineate the full extent of disease,
and aid in planning curative surgery. Drawbacks of MR include,
inability to accurately differentiate between concomitant Thyroid
disease and parathyroid pathology, and extremely high sensitivity
to patient motion, including respiration, swallowing and normal
patient movement, which may give rise to several confusing
artifacts.62
Selective venous catheterization with PTH measurement plays
a speciﬁc role in localizing a functioning parathyroid lesion. Study
results found selective venous sampling to have the highest
Table 4
Pathologic appearance of Parathyroid carcinoma24,68.
Macro
Mostly larger than 3 cm
Irrgegular
Gerayish-white
Hard
Adherent to adjacent tissue
May invade the ipsilateral thyroid gland, strup musles, RLN,
oesophagus and trachea
Micro
Trabecular pattern
Mitotic ﬁgures
Thick ﬁbrous bands
Capsular and blood vessel invasion
RLN, recurrent laryngeal nerve.
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available, and localizes tumors only to a region. Therefore, selective
venous sampling is recommended only when noninvasive imaging
studies do not identify a tumor site or results are equivocal.22
2.4. Biopsy
Cytologic and/or histologic analysis is traditionally the gold
standard of cancer diagnosis. However, due to procedure-related
complications such as bleeding, tumor seeding along the needle
tract following disruption of the tumor capsule and problems in
interpretation such as false negative diagnosis, biopsy of para-
thyroid carcinoma including ﬁne-needle aspiration cytology (FNAC)
should be avoided.67 Because there are no speciﬁc and valid criteria
to distinguish parathyroid carcinomas from their benign counter-
parts, making a deﬁnitive tissue diagnosis of parathyroid carcinoma
is difﬁcult. Thus, like all parathyroid lesions the diagnosis of para-
thyroid carcinoma is a clinical one and based on appearance at
operation. Intraoperatively, whereas parathyroid adenomas tend to
be soft, oval, and brownish-red in appearance, carcinomas tend to
be larger in size (>3 cm), grey-white, lobulated and have a dense,
ﬁbrous capsule. Adherence to, or invasion of, adjacent structures is
suggestive of malignancy. Histologic features of parathyroid carci-
noma have been described by Shanz and Castelman68 (Table 4).
They include: sheets or lobules of tumor cells separated by dense
ﬁbrous bands, mitotic ﬁgures, necrosis, capsular and vascular
invasion. Unfortunately, these classic pathologic features are not
always present in parathyroid carcinoma.69 Furthermore, some of
these features, particularly, mitotic ﬁgures and trabecular archi-
tecture also may be observed in parathyroid adenomas.70 There-
fore, much like other endocrine malignancies, histological
conﬁrmation of parathyroid carcinoma is based on clinical infor-
mation of the surgeon and an ultimate diagnosis of carcinoma can
be made with conﬁdence only after recurrence or distant metas-
tasis occurs.4
3. Treatment
3.1. Surgery
Surgery remains the only intervention offering the possibility of
a cure for parathyroid carcinoma (both functional and non-func-
tional) and the most effective treatment for recurrence as well. The
main treatment goal should be complete removal of the para-
thyroid cancer with negative margins. This includes, en bloc
resection of the primary lesion, ipsilateral thyroid lobectomy,
isthmectomy, tracheal skeletonization, and excision of any
adherent muscle.43,71 In case of recurrent parathyroid carcinoma,the aim of surgery is to reduce the tumor load and normalize serum
calcium.24 Because parathyroid carcinoma is slow-growing, and
distant metastases occur late in the course of the disease, initial
aggressive surgical approach is recommended when the diagnosis
is suspected at the time of parathyroidectomy to avoid local
recurrence.21 Simple parathyroidectomy in case of suspected
parathyroid carcinoma is inadequate and not recommended. En
bloc resection results in up to 50% a cure rate and has a survival
advantage over simple parathyroidectomy.29 More recent studies
have demonstrated simple parathyroidectomy to be inadequate,
with recurrence rates as high as 100%, and most recurrences
occurring within 1e6 years of initial treatment.72,73 Unfortunately,
a greater number of patients undergo simple parathyroidectomy as
their initial procedure for presumed primary hyperparathyroidism.
Data in the literature shows that only about 12% of parathyroid
carcinomas underwent primarily en bloc resection, as opposed to
80% who underwent parathyroidectomy alone.74,75 This trend is
a clear reﬂection of the diagnostic challenges prior to surgical
treatment. Patients who have an aggressive surgical resection with
clean margins at initial diagnosis have a longer disease-free and
overall survival than thosewho have a lesser procedure.21,29 Overall
survival directly correlates with the margin status of the initial
resection.76 For this reason, both preoperative suspicion and
intraoperative carful evaluation and recognition of parathyroid
carcinoma are of great importance. Along with en bloc resection,
bilateral neck exploration and identiﬁcation of all four parathyroid
glands is indicated for suspected parathyroid carcinoma, as it can
coexist with adenomas and hyperplasia.77 Sacriﬁce of the recurrent
laryngeal nerve can almost always be avoided unless it is involved
circumferentially by malignancy.38
Moreover, prophylactic and radical neck dissection is contro-
versial. Rates of lymph node involvement have varied from 32% in
a series published in 196971 to as low as 3% in the 1999 series
published by Hundal et al. 1 However, the high rates of lymph node
involvement may not actually be as high as some reports suggest,
since not all series distinguished cases with metachrouous lymph
node metastases, often occurring in the setting of local recurrence
from primary cases, thus inﬂating the lymph node involvement rate
to >30%. This suggests that primary lymph node metastasis in
parathyroid carcinoma is rare and radical neck dissection does not
improve overall survival. In addition, unnecessary prophylactic
radical neck dissection may increase the risk of postoperative
complications.21 Therefore, comprehensive lymphadenectomy is
not recommended except in cases, in which lymph node enlarge-
ment is apparent, there is extensive local invasion, or local recur-
rence is present.21,30,38
There is also controversy regarding the management of para-
thyroid carcinoma initially treated as primary hyperparathyroidism
and diagnosed postoperatively by histology. While some authors
suggest follow-up at intervals of 3 months with serial measure-
ments of serum calcium and PTH,78 others recommend re-explo-
ration of the neck and completion surgery particularly if the gross
characteristics were suggestive and the subsequent pathology is
aggressive, with vascular or capsular invasion.35 Given the high
recurrence rate of simple parathyroidectomy discussed earlier in
this section, the majority of surgeons tend to agree with the later
view because the ﬁrst reoperation may offer the last chance for
cure.
3.2. Radiotherapy
Following complete surgical resection, the most common
relapse pattern is local recurrence and distant metastases.43 In spite
of an extensive and a potentially curative surgery, recurrence rates
as high as 80% has been reported with the neck being the most
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nancy was considered to be not a radiosensitive neoplasm because
in the majority of patients studied, radiotherapy failed to slow
tumor growth and reduce metabolic complications.29,71,80
However, some recent reports have advocated postoperative radi-
ation therapy as a strategy for optimizing local control.38,76,81 In
selected patients, it appears to decrease the local recurrence rate
effectively and improves the disease-free interval.82 While this
approach offers a theoretical beneﬁt, the available literature on
adjuvant radiotherapy following resection of parathyroid carci-
noma is absent of prospective, randomized trials, mainly due to the
rarity of the disease. Therefore, most knowledge so far is from case
reports and small retrospective series and the role of adjuvant
radiation therapy following surgery remains unclear.
3.3. Chemotherapy
Chemotherapy has not been shown to improve survival or
correct hypercalcemia in patients with wide spread or unresectable
disease.19,45 A large number of agents including cyclophosphamide,
5-ﬂuorouracil and decarbazine, have been tested as single or
combination therapies without appreciable effects.83 Partial
responses with a marked drop in serum calcium lasting fromweeks
to several months have been observed in some individual cases84;
however, in general the results are largely disappointing.
3.4. Management of hypercalcemia
Patients with functioning parathyroid carcinoma who die of
disease do so as a result of complications of hypercalcemia rather
than from the tumor load itself.24,45,55,78, Control of hypercalcemia
resulting from parathyroid carcinoma can be best achieved through
surgical resection. Aggressive, often repeated resection of func-
tional local and distant recurrences is the most effective means of
achieving this end.47 However, in some patients, hypercalcemia
may be refractory to surgery, especially in those with unresectable
or widely metastatic disease, and these patients require other
treatment options. Management of hypercalcemic crisis initially
involves rehydration with intravenous 0.9% NaCl along with the
administration of loop diuretics to promote excretion of calcium.24
Most patients will be ﬂuid depleted and can require up to 4 L of
ﬂuid within the ﬁrst 24 h. Effective long-term control of hypercal-
cemia requires the addition of drugs that interfere with osteoclast-
mediated bone resorption or target the calcium-sensing receptor
(CaSR). Clodronate, etidronate and pamidronate are the most
widely used bisphosphnates that inhibit bone resorption.23,24
However, owing to signiﬁcant problems related to hypocalcemia
after surgery, intravenous use of bisphosphonates should be avoi-
ded if the patient is to undergo surgery within a few days. More-
over, most patients become unresponsive to bisphosphonates.
Plicamicin, although not very effective and toxic, is indicated as
a reserve drug for life-threatening hypercalcemia, unresponsive to
bisphosphonates.35 Calcitonin in the dose of 200 IU every 8 hmight
be helpful in decreasing albumin-adjusted calcium. Furthermore,
there is good evidence that calcimimetics, agents that suppress the
secretion of PTH by increasing the sensitivity of CaSR, such as
cinacalcet, can also be of value to control symptomatic hypercal-
cemia in parathyroid carcinoma patients.85,86 Likewise, immuni-
zation with PTH peptides and dendritic cell immunotherapy are
newer approaches that may have a promising future.87e91
3.5. Non-functioning parathyroid carcinoma
While functioning parathyroid carcinoma is a rare malignancy,
non-functioning parathyroid carcinoma is exceedingly rare withonly 19 reported cases in the last 100 years.4,81 Patients have
normal serum calcium and PTH levels and do not present with
symptoms of hypercalcemia. Therefore, non-functioning para-
thyroid carcinoma is usually clinically silent until it presents with
advanced disease. A palpable neck mass is present in more than
80% of patients.4,8,24 Other presenting symptoms may include
dysphagia and hoarseness due to involvement of the recurrent
laryngeal nerve.81 Similar to functioning parathyroid carcinoma,
the mainstay of treatment of non-functioning parathyroid cancer is
surgery. At present, only en bloc resection of all detectable tumor is
associated with improvement in long-term prognosis. However,
overall outcome is dismal, in part because there is no speciﬁc
serologic marker and early detection of recurrence is almost
impossible. In contrast to patients with functioning parathyroid
carcinoma who die of metabolic complications of hypercalcemia,
Patients who die of non-functioning parathyroid carcinoma
succumb to systemic tumor burden, mostly within the ﬁrst two
years of diagnosis.4,92,93
3.6. Staging and prognosis
When a diagnosis of cancer is suspected, the initial priority is to
determine staging for treatment, particularly resectability. Unfor-
tunately, there are no accepted staging criteria for parathyroid
carcinoma. The usual TNM staging system cannot be applied to
parathyroid carcinoma for the following reasons: ﬁrst, parathyroid
carcinoma spreads to adjacent lymph nodes, but usually after local
recurrence and primary lymph node metastasis is infrequent1,38;
and second, tumor size does not appear to play a role in prog-
nosis.1,30,85 So, staging is clinical and best done with an interdisci-
plinary input.
Regarding prognosis, parathyroid carcinoma is a disease with an
often indolent but progressive course. It has a tendency to inﬁltrate
in to the surrounding muscles, and vital anatomical structures. Its
prognosis is quite variable; and no one characteristic correlates
predictably with outcome. Neither tumor size nor lymph node
status appears to predict survival.1 Early recognition and en bloc
resection of the primary lesion at the time of the initial operation
carry the best prognosis.35 The mean time to recurrence is
approximately 3 years (range 1e20 years).21,79 Five-year survival
rates vary from 40% to 86%.35 The overall 10-year survival rate is
reported to be 49%.1 However, 10-year survival rates as high as 77%
have been also reported.38 The higher survival rate at 10 years in
this group may relate to an improvement in supportive care in
general and, more speciﬁcally, in the control of hypercalcemia.
4. Summary
Parathyroid carcinoma is an extremely rare tumor that
continues to present formidable challenges in diagnosis and
treatment. It is an aggressive disease with propensity to multiple
recurrences that portends poor outcome. In spite of the best
surgical effort, the recurrence rate of parathyroid carcinoma is as
high as 80% with survival rates <50% at 10 years. It is likely that the
diagnostic uncertainty which mainly results from the unusual
biological behavior of this malignancy contributes to inadequate
initial surgical treatment. This decreases the possibility of achieving
a histological margin-negative resection, as this is the patient’s only
hope for cure and prolonged disease-free survival. It means, major
improvement in the survival of patients with this cancer will
probably not result from more aggressive or advanced surgical
techniques only. Instead, additional efforts should be directed at
early detection, which is the main problem, and novel additional
treatments derived from basic research. Effort should be taken to
establish more reliable diagnostic tools. New molecular studies,
W.T. Kassahun, S. Jonas / International Journal of Surgery 9 (2011) 13e1918including evaluation of HRPT2/paraﬁbromin as well as advances in
imaging, may aid to achieve this objective and improve outcomes in
this devastating disease. Furthermore, there are only sporadic
reports of successful adjuvant radiation therapy and currently there
are no data supporting the routine use of chemotherapy outside
a clinical trial. These are additional avenues of study that need to be
undertaken.
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